

4th Annual Hereditary Cancer Symposium for Health Care Providers

-Virtual Course -

April 16-17, 2021

Program Chairs

Banu Arun, MD

Y. Nancy You, MD, MHSc

Yoheved "Kevi" Gerstein, MS, CGC

Autumn Vara, MS, CGC



THE UNIVERSITY OF TEXAS

MD Anderson
~~Cancer~~ Center

Making Cancer History®

The goal of this symposium is to provide health care professionals with knowledge and skills resulting in the ability to improve patient care.

EDUCATIONAL OBJECTIVES

After attending the Symposium, participants should be able to

- Implement guidelines to assess and screen high-risk patients in daily practice;
- Recognize and document key features associated with potential hereditary cancer predisposition adequately to refer at-risk patients for cancer assessment;
- Recognize and implement surgical interventions, screening protocols, and systemic therapies appropriate for specific hereditary cancer predisposition syndromes/genes;
- Recognize impact of genetic testing results on the patient, psychosocially and medically, for current and long-term management;
- Identify a genetic counseling service delivery model that fits their clinical practice and implement a referral strategy;
- Differentiate the utility of various genetic testing modalities commonly used related to oncology risk and care .

EDUCATIONAL METHODS

Lectures – Panel Discussions – Case Studies – Question and Answer Sessions

TARGET AUDIENCE

This Symposium should be of value to physicians, advanced practice providers, nurses, and oncology genetic counselors.

EVALUATION

A course evaluation survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES

Certificates will be provided to participants upon completion of the symposium evaluation.

NURSING

The University Of Texas MD Anderson Cancer Center Is accredited with distinction as a provider of Nursing Continuing Professional Development by The American Nurses Credentialing Center's Commission on Accreditation The University of Texas MD Anderson Cancer Center designates this internet live course will award 9.16 Nursing Continuing Professional Development (NCPD) credit

GENETIC COUNSELOR CREDITS

NSGC Category 1 CEU credit will be available for genetic counselors.

PROGRAM PLANNING COMMITTEE

Banu Arun, MD, Co-Chair
Breast Medical Oncology

Yoheved "Kevi" Gerstein, MS, CGC, Co-Chair
Clinical Cancer Genetics

Patti Heitz, MEd, BSN, RN, OCN
Professional Development & Nursing Education

Walter Knowles, MBA
Clinical Cancer Genetics

Ann Molinaro, BSBM
Clinical Cancer Genetics

Julie Moskowitz, MS, CGC
Clinical Cancer Genetics

Susan Reilly, MS, CGC
Clinical Cancer Genetics

Donika Saporito, MS, CGC
Clinical Cancer Genetics

Christina Serna-Blanco, MSN, APRN, WHNP-BC
Breast Medical Oncology

Sreejesh Shanker, PhD
Clinical Cancer Genetics

Grace Tran, MS, CGC
Clinical Cancer Genetics

Autumn Vara, MS, CGC, Co-Chair
Clinical Cancer Genetics

Y. Nancy You, MD, MSHc, Co-Chair
Surgical Oncology

Linda Hill
Clinical Cancer Genetics

Constance C. Tierney, CMP
Continuing Professional Education



Program

FRIDAY, APRIL 16, 2021

8:15 a.m.	INTRODUCTION AND WELCOME Banu Arun, MD
8:25	GENETICS IN ONCOLOGY CARE Maureen Mork, MS, CGC
9:05	CANCER PREVENTION FOR HEREDITARY CANCERS Nadine Rayes, MS, CGC Banu Arun, MD Karen Lu, MD Y. Nancy You, MD, MHSc
9:35	INTEGRATING GENETICS EVALUATION INTO CANCER SURVIVORSHIP CARE Erica Bednar, MS, MPH, CGC
9:45	FAMILY HISTORY COLLECTION IN THE CLINICAL SETTING Victoria (Tori) McClosky, BSN, RN
9:55	Break
10:05	TREATMENT IMPLICATIONS OF GENETIC TESTING RESULTS: SYSTEMIC THERAPY FOR BREAST CANCER Rachel Layman, MD
10:35	TREATMENT IMPLICATIONS OF GENETIC TESTING RESULTS: SYSTEMIC THERAPY FOR OVARIAN CANCER Larissa Meyer, MD
11:05	TREATMENT IMPLICATIONS OF GENETIC TESTING RESULTS: IMMUNOTHERAPY FOR COLORECTAL CANCER Kanwal Raghav, MD
11:35	Lunch Break
12:35 p.m.	GENETICS IN THE PEDIATRIC AND YOUNG ADULT POPULATION Jessica Corredor, MS, CGC Michael Roth, MD

1:15	UPDATES ON HEREDITARY POLYPOSIS Julie Moskowitz, MS, CGC Selvi Thirumurthi, MD
1:55	Break
2:05	INTEGRATING UNIVERSAL GERMLINE GENETIC TESTING INTO CLINICAL PRACTICE Tilu Ninan, APRN, ANP-C
2:20	ALTERNATIVE SERVICE DELIVERY MODELS IN ONCOLOGY GENETICS Kate Principe, MS, CGC Rachel Bluebond, MMSc, CGC
2:50	POLYGENIC RISK SCORES: CALCULATIONS AND USE IN CLINICAL MANAGEMENT Christopher Amos, MD
3:50	CLOSING REMARKS Karen Lu, MD
4:00	Adjourn

SATURDAY, APRIL 17, 2021

8:30 a.m.	WELCOME Autumn Vara, MS, CGC
8:40	GENETIC TESTING TECHNOLOGIES: SOMATIC TESTING, GERMLINE TESTING, AND DIRECT-TO-CONSUMER TESTING Molly Daniels, MS, CGC
9:40	FERTILITY PRESERVATION IN ONCOLOGY CARE Terri Woodard, MD
10:00	Break
10:15	PREIMPLANTATION GENETIC SCREENING FOR HEREDITARY CANCER Sandra Darilek, MS, CGC
10:45	EXPERT REVIEW PANEL: SUBMITTED CASES DISCUSSED Autumn Vara MS, CGC; Maureen Mork, MS, CGC; Julie Moskowitz, MS, CGC; Grace Tran, MS, CGC
11:25	PATIENT EXPERIENCE: LIFE AFTER GENETIC TESTING Bryan Joyce
11:45	CLOSING REMARKS Y. Nancy You, MD, MHSc
Noon	Adjourn

MD ANDERSON FACULTY

Banu Arun, MD

Breast Medical Oncology

**Erica Bednar, MS, MPH,
CGC**

Clinical Cancer Genetics

Jessica Corredor, MS, CGC

Clinical Cancer Genetics

Molly Daniels, MS, CGC

Clinical Cancer Genetics

Rachel Layman, MD

Breast Medical Oncology

Karen Lu, MD

*Gynecological Oncology and
Reproductive Medicine*

**Victoria (Tori) McClosky,
BSN, RN**

Breast Center

Larissa Meyer, MD

*Gynecologic Oncology and
Reproductive Medicine*

Maureen Mork, MS, CGC

Clinical Cancer Genetics

Julie Moskowitz, MS, CGC

Clinical Cancer Genetics

Tilu Ninan, APRN, ANP-C

*CPB Provider Income
& Activity*

Kanwal Raghav, MD

GI Medical Oncology

Nadine Rayes, MS, CGC

Clinical Cancer Genetics

Michael Roth, MD

Pediatrics

Selvi Thirumurthi, MD

Gastroenterology

Grace Tran, MS, CGC

Clinical Cancer Genetics

Autumn Vara, MS, CGC

Clinical Cancer Genetics

Terri Woodard, MD

*Gynecologic Oncology and
Reproductive Medicine*

Y. Nancy You, MD, MHSc

Surgical Oncology

GUEST FACULTY

Christopher Amos, MD

*Associate Director of
Quantitative Science
Baylor College of Medicine
Houston, Texas*

Rachel Bluebond, MMSc, CGC

*Ambry Genetics
Houston, Texas*

Sandra Darilek, MS, CGC

*Department of Molecular
and Human Genetics
Baylor College of Medicine
Houston, Texas*

Bryan Joyce

*Patient
San Antonio, Texas*

Kate Principe, MS, CGC

*Texas Oncology
Houston, Texas*

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail Continuing Professional Education. All responses will be forwarded to the Program Chairs for consideration.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

REGISTRATION INFORMATION

The 4th Annual Hereditary Cancer Symposium for Healthcare Providers opens at 8:15 a.m. on Friday, April 16, 2021 and the symposium ends at noon on Saturday, April 17, 2021. Advanced registration is encouraged as space and materials are limited. Please see the registration form for applicable fees.

The full symposium registration fee includes the tuition, final program, access to course virtual program.

REGISTRATION FEES

- ☐ Physicians, NPs, PAs\$75
- ☐ Other HealthCare Professionals
(RNs, Advanced Practice Providers, GCs)\$50
- ☐ Non-Clinical\$25
- ☐ Trainees/Students\$25

Register on-line at <https://mdanderson.cloud-cme.com/Hereditary2021>.

We accept the following forms of payment:

1. Check (payable through U.S. Banks only)
2. Credit cards (Master Card, VISA, and American Express)

A receipt/confirmation letter will be sent to you within ten working days of receipt of your registration.

The Department of Continuing Professional Education reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of Continuing Professional Education is limited to the registration fee. Continuing Professional Education will refund the full registration fee.

The Department of Continuing Professional Education reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

THE UNIVERSITY OF TEXAS
MD ANDERSON CANCER CENTER
CME/CONFERENCE MANAGEMENT, UNIT 1781
176700/30/122108/41
PO BOX 301407
HOUSTON, TEXAS 77230-1407